Acquisition broadens BioreclamationIVT’s disease-state biospecimen capabilities, particularly in oncology, and expands its scientific service offerings for diagnostic and drug development researchers
BioreclamationIVT, a leading provider of biospecimens and related services, recently announced that it has acquired Asterand Bioscience, a global provider of high quality, well-characterized human tissue and research solutions with a focus on the oncology market. Asterand Bioscience advances drug research by accelerating target identification and biomarker validation, and improving drug candidate selection to increase the likelihood of clinical success.
“We are delighted that Asterand Bioscience’s talented staff is joining BioreclamationIVT. This is a great fit between two complementary companies,” said BioreclamationIVT Chief Executive Officer Jeff Gatz. “This acquisition will expand BioreclamationIVT’s portfolio of highly-annotated disease-state biospecimens. After combining Asterand Bioscience’s first-rate oncology tissue sourcing network with our existing strength in procuring disease-state tissue and clinical biofluids, BioreclamationIVT will become the market leader in disease-state biospecimens and a top resource for researchers focused on precision medicine. The addition of Asterand Bioscience’s tissue services and PhaseZERO research services groups will allow the combined company to offer a full research workflow solution, ranging from specimen sourcing through experimental design to data collection. BioreclamationIVT’s new offerings will include target and biomarker validation using histology and molecular techniques, and compound evaluation using cell-based model systems.”
“We are committed to extending BioreclamationIVT’s industry leading position through targeted investments and focused M&A activity,” said David Spaight, Chairman of BioreclamationIVT. “The acquisition of Asterand Bioscience is an important component of our strategy to provide biopharmaceutical researchers with the highest quality, well-annotated biospecimens and a full suite of scientific services.”
“We are pleased to be joining BioreclamationIVT and beginning the next phase of our company’s growth. It will be exciting to see the positive impact that our combined expertise and resources will have on diagnostic and drug development globally,” said Asterand Bioscience Chief Operating Officer and Chief Financial Officer John Canepa.
BioreclamationIVT is a worldwide provider of biological products to the life sciences and pharmaceutical industries. BioreclamationIVT specializes in control and disease-state matrices manufactured from human and animal biological specimens and has recently expanded its offering to include cell processing and phenotypic screening services. This portfolio of products and services is utilized throughout the drug discovery and development research workflows, and directly supports precision medicine research by coupling clinical information with numerous disease-state fluids and tissues. BioreclamationIVT’s reputation for providing exceptional customer service coupled with the highest quality specimens and services have made it the first-choice supplier for biospecimens for more than 35 years. For more information, visit www.bioreclamationivt.com.
About Asterand Bioscience
Asterand Bioscience is the leading global provider of high quality, well-characterized human tissue and human tissue-based research solutions to drug discovery scientists. Our mission is to provide human-based solutions to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with increased likelihood of clinical success. From our offices in Detroit, MI and Royston, U.K., our employees are focused on providing services and products to accelerate drug discovery research from target identification through to compound evaluation and drug safety. For more information, visit www.asterandbio.com.